PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
Xian-De Liu(The University of Texas MD Anderson Cancer Center), Eric Jonasch(The University of Texas MD Anderson Cancer Center)
Cited by 173
Related Papers
SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma
|Clinical Cancer Research|2023|13